Stock research
ESLA Estrella Immunopharma, Inc.
Healthcare • Biotechnology
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States....…
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
5Y change
-92.35%
Range high
$21.25
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in ESLA?
Price
Showing 5Y history. Source: FMP historical price full.
- Prev Close
- $0.71
- Day High
- $0.75
- Day Low
- $0.69
- 52w High
- $3.15
- 52w Low
- $0.69
- Volume
- 23,000
- Avg Volume
- Beta
- 0.858
* TTM/most recent where available
Company
- Ticker
- ESLA
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Cheng Liu
- Employees
- 3
- Website
- www.estrellabio.com
Key Metrics
- Market Cap
- 32.1M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).